ExxonMobil and Porsche Expand Motorsports Technology Partnership Into Formula E
6.9.2019 16:00:00 EEST | Business Wire | Press release
ExxonMobil is expanding its global business and technical partnership with Porsche by teaming with the luxury German automaker on its Formula E series car for the 2019 / 2020 season. The new partnership represents ExxonMobil’s first entry into electric motorsports.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190906005023/en/
ExxonMobil is expanding its global business and technical partnership with Porsche by teaming with the luxury German automaker on its Formula E series car for the 2019 / 2020 season. (Photo: Business Wire)
Starting from the first race in Saudi Arabia at the end of this year, ExxonMobil will provide Mobil-branded high-performance electric powertrain fluids to Porsche, developed specifically to meet the specialized demands of electric vehicles.
“Our entry into Formula E with Porsche not only represents an expansion to our successful business relationship, but an expansion of a winning partnership in racing,” said Russ Green, vice president, finished lubricants at ExxonMobil. “As Porsche begins to compete and demonstrate the capabilities of its electric vehicle technology, ExxonMobil is engineering a full suite of Mobil-branded lubricants to help the new Porsche Formula E team build on its legacy of racing success around the world. Motorsport provides the ultimate proving ground to continue to develop high-performance lubricants and fluids.”
Vehicles competing in electric motorsports benefit from high-performance lubricant technology that provides specialized advantages needed for the car’s battery pack including electrical conductivity, cooling capabilities and material compatibility.
“As a key technical partner of more than 20 years, no other lubricant supplier understands the Porsche performance philosophy like ExxonMobil,” said Fritz Enzinger, vice president, Porsche Motorsport. “ExxonMobil has not only been a valuable partner for our commercial business, but an important teammate in our pursuit of wins and championships from Sebring to Le Mans. They were a natural addition to our Formula E team as we enter an exciting new era of racing for Porsche.”
The new technical partnership joins ExxonMobil’s existing roster of global motorsports activities with Porsche including the World Endurance Championships, IMSA WeatherTech SportsCar Championship, Porsche Mobil 1 Supercup, Porsche Carrera Cup and numerous customer racing activities around the world.
About ExxonMobil
ExxonMobil, the largest publicly traded international oil and gas company, uses technology and innovation to help meet the world’s growing energy needs. ExxonMobil holds an industry-leading inventory of resources, is one of the largest refiners and marketers of petroleum products, and its chemical company is one of the largest in the world.
About ExxonMobil in Motorsports
Racing provides ExxonMobil and its lubricants and fuels brands the ultimate testing ground to improve the technology in our range of oil, lubricants and fuels. Each race season, our advanced products go to work to help improve vehicle performance and efficiency. ExxonMobil products serve as the lubricant of choice for many of the world’s top race teams competing in highly demanding motorsports series. The knowledge we gain through these partnerships helps our scientists and engineers push the boundaries in developing cutting-edge technologies.
ExxonMobil remains proud partners with Aston Martin Red Bull Racing, Stewart-Haas Racing in NASCAR’s Sprint Cup Series; Porsche, Bentley and TOYOTA GAZOO Racing in the FIA World Endurance Championship; Corvette Racing, Porsche North America, Lexus and Acura/Caterpillar in the IMSA WeatherTech SportsCar Championship; and numerous teams competing in series around the world.
For more information about ExxonMobil and its brands, visit www.exxonmobil.com or follow us on Twitter www.twitter.com/exxonmobil.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190906005023/en/
Contact information
Media Relations
832-625-4000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom